What You Can Learn From Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) P/E

Simply Wall StJan 2 06:41 ET

Neurocrine Biosciences, Inc. Selects PANTHERxRare Specialty Pharmacy for Distribution of Crenessity (Crinecerfont)

PR NewswireDec 23, 2024 14:54 ET

Neurocrine Is Maintained at Overweight by Barclays

Dow JonesDec 23, 2024 07:49 ET · Ratings

Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $160

Moomoo NewsDec 23, 2024 07:31 ET · Ratings

Wedbush Raises Price Target on Neurocrine Biosciences to $154 From $148, Keeps Outperform Rating

MT NewswiresDec 23, 2024 06:39 ET · Ratings

Barclays Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165

Moomoo NewsDec 23, 2024 05:34 ET · Ratings